- Home
- WOK vs NLSP Comparison
WOK vs NLSP Comparison
Compare WOK & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- NLSP
- Stock Information
- Founded
- WOK 2002
- NLSP 2015
- Country
- WOK China
- NLSP Switzerland
- Employees
- WOK N/A
- NLSP N/A
- Industry
- WOK
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- NLSP Health Care
- Exchange
- WOK NYSE
- NLSP Nasdaq
- Market Cap
- WOK 5.8M
- NLSP 5.8M
- IPO Year
- WOK 2024
- NLSP 2021
- Fundamental
- Price
- WOK $0.52
- NLSP $1.62
- Analyst Decision
- WOK
- NLSP
- Analyst Count
- WOK 0
- NLSP 0
- Target Price
- WOK N/A
- NLSP N/A
- AVG Volume (30 Days)
- WOK 159.0K
- NLSP 26.4K
- Earning Date
- WOK 02-03-2025
- NLSP 05-27-2025
- Dividend Yield
- WOK N/A
- NLSP N/A
- EPS Growth
- WOK N/A
- NLSP N/A
- EPS
- WOK N/A
- NLSP N/A
- Revenue
- WOK $11,506,440.00
- NLSP N/A
- Revenue This Year
- WOK N/A
- NLSP N/A
- Revenue Next Year
- WOK N/A
- NLSP N/A
- P/E Ratio
- WOK N/A
- NLSP N/A
- Revenue Growth
- WOK N/A
- NLSP N/A
- 52 Week Low
- WOK $0.36
- NLSP $1.30
- 52 Week High
- WOK $8.45
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- NLSP 53.77
- Support Level
- WOK N/A
- NLSP $1.58
- Resistance Level
- WOK N/A
- NLSP $1.75
- Average True Range (ATR)
- WOK 0.00
- NLSP 0.10
- MACD
- WOK 0.00
- NLSP 0.01
- Stochastic Oscillator
- WOK 0.00
- NLSP 55.73
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.